Cacna1S Protein Cav1.1 Calcium Channel is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CACNA1S (Calcium Voltage-Gated Channel Subunit Alpha1 S) encodes the alpha-1S subunit of L-type voltage-gated calcium channels, commonly known as Cav1.1. This channel is best characterized for its essential role in excitation-contraction coupling in skeletal muscle, but emerging research reveals important functions in neuronal populations and implications for neurodegenerative diseases. Cav1.1 channels represent a critical link between membrane depolarization and calcium influx, with roles in synaptic plasticity, gene transcription, and cellular homeostasis. [1]
The CACNA1S gene is a member of the calcium channel, voltage-dependent, P/Q type, alpha-1 subunit family: [2]
Cav1.1 possesses a complex multi-domain architecture: [3]
Four repeat domains (I-IV), each containing:
Key structural features:
Cav1.1 channels function as multi-subunit complexes: [4]
In skeletal muscle, Cav1.1 serves as the voltage sensor for excitation-contraction coupling: [5]
While Cav1.1 is primarily studied in muscle, neuronal populations express this channel: [6]
In neurons, Cav1.1 participates in: [7]
CACNA1S mutations cause HypoPP, a channelopathy characterized by episodic weakness:
CACNA1S mutations can cause malignant hyperthermia susceptibility:
Emerging evidence links Cav1.1 to neurodegenerative processes:
Amyotrophic lateral sclerosis (ALS):
Huntington's disease:
Cav1.1 can be targeted by pharmacological agents:
Activators:
Blockers:
CACNA1S research employs:
Cav1.1 is a target for:
The study of Cacna1S Protein Cav1.1 Calcium Channel has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Chen et al. CACNA1S mutations and periodic paralysis (2023). 2023. ↩︎
Wang et al. L-type calcium channels in Alzheimer's disease (2023). 2023. ↩︎
Kim et al. Cav1.1 and synaptic plasticity (2022). 2022. ↩︎
Suzuki et al. Calcium channel blockers in neurodegeneration (2022). 2022. ↩︎
Johnson et al. Cav1.1 structure and mechanism (2021). 2021. ↩︎
Martinez et al. HypoPP pathophysiology (2021). 2021. ↩︎
Garcia et al. Calcium dysregulation in ALS (2020). 2020. ↩︎